ContextVision Files Patent on Skeleton Imaging

STOCKHOLM--()--Regulatory News:

ContextVision (OSE:COV):

ContextVision, a leading provider of medical imaging software, has filed a patent application on a new technology for the visualization of the skeleton from 3D ultrasound. The technology improves the potential for early discovery of skeletal irregularities in unborn babies.

Based on the technology now being patented, a new product feature named SkeletalView is developed. The feature will be integrated into ContextVision’s groundbreaking 3D rendering product, REALiCE, which was launched in September.

SkeletalView enables the clinicians to obtain a more accurate view of the fetal skeleton during pregnancy. The new feature helps the clinicians examine the fetus for spontaneous fractures and skeletal malformations. It also facilitates the measurement of bone structures.

“Our new visualization product REALiCE has received significant industry attention since it was launched a few weeks ago. SkeletalView adds further diagnostic value, and we expect that the product will be even more attractive to manufacturers of medical imaging equipment going forward,” said ContextVision’s CEO, Anita Tollstadius.

The added feature will be demonstrated at the international RSNA (Radiological Society of North America) meeting in Chicago at the end of this month.

About ContextVision

ContextVision’s technology provides doctors with improved images, which are crucial for accurate diagnosis and treatment. ContextVision is the industry leader in medical image analysis and enhancement software, with more than 150 000 installations worldwide through its OEM customers. The company started out as an industry pioneer more than 30 years ago, and is today developing the next generation of medical imaging software for 2D/ 3D/ 4D ultrasound, MRI, X-Ray, mammography and CT. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit www.contextvision.com

This information was brought to you by Cision http://news.cision.com

Contacts

Press Office
+ 46 8 750 35 50

Contacts

Press Office
+ 46 8 750 35 50